|
||||||
|
ARROW INTERNATIONAL REPORTS ON STATUS OF CorAide™ CLINICAL TRIALS READING, PA, June 7, 2005 – Arrow International, Inc. (Nasdaq: ARRO) announced today that three additional patients have been implanted with the Company’s CorAide™ continuous flow left ventricular assist system (LVAS) as part of its clinical trial of the device in Europe. In total, five patients have now received CorAide™ LVAS implants since the clinical trial of the device was resumed in February 2005. The Diabetes and Heart Center in Bad Oeynhausen, Germany has now implanted four CorAide™ LVAS devices. Physicians at the Center reported that the device is performing well and allowing patients to recover rapidly from the operative procedure and begin ambulation. The first two CorAide™ patients have been discharged to their homes and have reached the endpoint of the study by exceeding 90 days on the device. Arrow also announced that another clinical trial center, Policlinico di San Matteo in Pavia, Italy, implanted its first CorAide™ LVAS as part of the study. The patient continues to recover and has been discharged. An additional trial center in Germany, Deutsches Herzzentrum Berlin, will begin screening patients following its completion of the CorAide™ training program later this month. The CorAide™ LVAS features a Portable Electronic Module (PEM) which responds automatically to the changing physiologic needs or demands of the patient, increasing or decreasing the pump’s speed with corresponding changes in blood flow in response to the patient’s level of activity. The clinical trial experience has shown that the CorAide™ LVAS automatic control mode is working as intended. Carl G. Anderson, Jr., Arrow’s Chairman and Chief Executive Officer, commented, “We are pleased with the response from our investigators at the trial centers on the performance of the CorAide™ LVAS and the promising clinical outcomes. While these early results are encouraging, we believe that additional clinical experience is needed in order for us to have sufficient information to make an assessment of the device and its performance. We hope to gather this additional information as we continue to enroll patients in the European clinical trial.” Leonard A.R. Golding, M.D., who led the team of researchers at The Cleveland Clinic in pioneering the implantable CorAide™ LVAS stated, “The relationship between The Cleveland Clinic and Arrow International in developing this unique cardiac assist device serves as a prototype for how companies and academic medical centers can collaborate for the advancement of patient care. The combined effort between The Cleveland Clinic and Arrow International is enhancing the opportunity research subjects have for good clinical outcomes. This close collaboration extends to the European clinical trial." Additionally, the Company reported that Steven W. Boyce, Surgical Director of the Heart Failure Program at Washington Hospital Center, will discuss the CorAide™ LVAS in a presentation today at “A Day With The Docs,” a private investor program held at the Washington Hospital Center in Washington, DC. Wayne Richenbacher, M.D. from the University of Iowa Hospital & Clinics will also discuss the CorAide™ clinical trial results as part of his presentation, “Breaking News,” at the meeting of the American Society of Artificial Internal Organs (ASAIO) in Washington, DC on Saturday, June 11. The slides shown by Drs. Boyce and Richenbacher in their respective presentations will be available for viewing following their presentations on the Company’s website at http://www.arrowintl.com/presentations/. Company Information Arrow International, Inc. (Nasdaq: ARRO) develops, manufactures and markets a broad range of clinically advanced, disposable catheters and related products for critical and cardiac care. The Company’s products are used primarily by anesthesiologists, critical care specialists, surgeons, emergency and trauma physicians, cardiologists, interventional radiologists, electrophysiologists, and other health care providers. Arrow International’s news releases and other company information can be found on its website at http://www.arrowintl.com. Safe Harbor Statement “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: This news release provides historical information and includes forward-looking statements. Although the Company believes that the expectations in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to have been correct. The forward-looking statements are based upon a number of assumptions and estimates that, while presented with numerical specificity and considered reasonable by the Company, are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies which are beyond the control of the Company, and upon assumptions with respect to future business decisions which are subject to change. Accordingly, the forward-looking statements are only an estimate, and actual results will vary from the forward-looking statements, and these variations may be material. Consequently, the inclusion of the forward-looking statements should not be regarded as a representation by the Company of results that actually will be achieved. Forward-looking statements are necessarily speculative in nature, and it is usually the case that one or more of the assumptions in the forward-looking statements do not materialize. Investors are cautioned not to place undue reliance on the forward-looking statements. In connection with the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, the Company cautions the reader that, among others, the factors below, which are discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended August 31, 2004 and in its other filings with the Securities and Exchange Commission, could cause the Company’s results to differ materially from those stated in the forward-looking statements. These factors include: (i) stringent regulation of the Company’s products by the US Food and Drug Administration and, in some jurisdictions, by state, local and foreign governmental authorities; (ii) the highly competitive market for medical devices and the rapid pace of product development and technological change in this market; (iii) pressures imposed by the health care industry to reduce the cost or usage of medical products and services; (iv) dependence on patents and proprietary rights to protect the Company’s trade secrets and technology, and the need for litigation to enforce or defend these rights; (v) risks associated with the Company’s international operations; (vi) potential product liability risks inherent in the design, manufacture and marketing of medical devices; (vii) risks associated with the Company’s use of derivative financial instruments; and (viii) dependence on the continued service of key members of the Company’s management.
|
|
 |
|||